Arvinas Inc. (ARVN) PT Raised to $116 at BMO Capital

August 5, 2021 3:59 PM EDT
Get Alerts ARVN Hot Sheet
Price: $96.48 +2.42%

Rating Summary:
    14 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

BMO Capital analyst Matthew Luchini raised the price target on Arvinas Inc. (NASDAQ: ARVN) to $116.00 (from $111.00) while maintaining a Outperform rating.

The analyst commented, "We remain Outperform rated on ARVN following 2Q earnings and corporate update. Key data catalysts are on track with ARV-471 dose escalation update expected at SABCS (Dec 7-10) and ARV-110 full Phase 1 and interim Phase 2 ARDENT data in metastatic castration-resistant prostate cancer (mCRPC) also expected in 2H21. Overall we remain positive on ARVN shares keeping our focus on clinical execution ahead of key updates. We update our model for 2Q results, increasing our target to $116 from $111. Reiterate Outperform."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

BMO Capital, Earnings